2 most recent filings and news items mentioning TECH. Updated every 60 seconds.
M&AJun 25, 2026Positive
Merck KGaA entered into a definitive agreement to acquire Bio-Techne for $73 per share, representing an enterprise value of $11.3 billion. This transaction is expected to immediately accretive to sales growth and EBITDA, strengthening Merck's presence in the life sciences market.
View filing at SEC.gov →
NewsJun 25, 2026Neutral
Merck To Acquire Bio-Techne For $73 Per Share In Cash At EV Of $11.3B; Deal Expected To Be Immediately Accretive To Sales Growth And EBITDA Pre Margin And EPS Pre Accretive By Year 3 Post-Closing
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.